New treatment trial for PTSD

 A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults with Post-Traumatic Stress Disorder (PTSD)


Aim: To evaluate the safety and efficacy of BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) 

Method:  A total of 192 patients are planned to be enrolled in this randomized, double-blind, placebo-controlled study. The study will compare the effect of three different doses of BNC210 to placebo, on the symptoms of PTSD.  Patients will be treated for 12 weeks and will be assessed using a variety of psychiatric and cognitive assessment tools. 

Project status: This study is currently recruiting in Australia and will open soon in the USA. 

Study team: Professor Jayashri Kulkarni, Professor Paul Fitzgerald, Dr Matthew Kang, Dr Fenny Muliadi, Ms Fiona James

For more information, please contact Fiona James on fiona.james@monash.edu or (03) 9076 2404
 
 
AttachmentSize
BNC210.007_Study Brochure_V1.0_161024.pdf2 MB

 MAPrc Monash Alfred Psychiatry Research Centre, Level 4, 607 St Kilda Road, Melbourne 3004

 © MAPrc 2013. Designed and hosted by Infoxchange Australia